Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00081731 · ClinicalTrials.gov registry record · Phase 3
Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
A Phase 3 study, sponsored by Baim Institute for Clinical Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 947
- Enrollment target
NCT00081731: Completed Phase 3 study, sponsored by Baim Institute for Clinical Research.
NCT00081731 is a Phase 3 study that has completed, run by Baim Institute for Clinical Research. The registered enrollment target is 947 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00081731, a Phase 3 study, has completed, sponsored by Baim Institute for Clinical Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 947 participants
- Enrollment target
Study Summary
This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
Primary Outcome
Only the first event per participant is included in the composite
Interventions
- DRUG Atacand/HCT, Caduet
- PROCEDURE GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 947 participants |
| Start Date | 2004-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
What the finished NCT00081731 record still lists
NCT00081731 is an interventional study that assigns participants to a tested intervention. The registered 947 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 2 interventions - of which Atacand/HCT, Caduet is the first listed.
NCT00081731 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00081731 about?
NCT00081731 is a clinical study titled "Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions". This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
What is the current status of trial NCT00081731?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 947 participants. The study started on 2004-04. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00081731?
The interventions under investigation include: Atacand/HCT, Caduet (DRUG), GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) (PROCEDURE).
Who is sponsoring clinical trial NCT00081731?
This trial is sponsored by Baim Institute for Clinical Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00081731's enrollment target sits among peer trials
947 334th of 2000 higher than 1,667 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia